
Ocular Therapeutix OCUL
$ 8.38
-1.35%
Annual report 2025
added 02-05-2026
Ocular Therapeutix Cash Conversion Cycle 2011-2026 | OCUL
Annual Cash Conversion Cycle Ocular Therapeutix
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 174 | 63.3 | -32.5 | -110 | -60.9 | -180 | -143 | -2.12 K | -2.71 K | -1.6 K | -2.05 K | -4.59 K | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 174 | -4.59 K | -1.11 K |
Quarterly Cash Conversion Cycle Ocular Therapeutix
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 47.3 | 89.9 | 156 | - | 98.8 | 5.74 | -42.3 | - | 51.4 | -13.4 | -92.9 | - | -100 | -5.96 | -36.2 | - | -58 | -115 | -71.2 | - | -116 | -314 | 45.9 | 103 | 18.5 | -24.8 | -1.55 K | 36.4 | -2.14 K | -1.61 K | -3.48 K | 42.4 | 39.4 | 47.1 | 45.7 | 44.6 | 23.9 | - | 19.2 | 40 | 37.5 | 51.3 | 72.9 | 59.5 | 210 | 310 | 978 | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 978 | -3.48 K | -173 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Arbutus Biopharma Corporation
ABUS
|
50 | $ 4.5 | 0.45 % | $ 862 M | ||
|
Agenus
AGEN
|
-25.8 K | $ 3.64 | 9.31 % | $ 108 M | ||
|
Agios Pharmaceuticals
AGIO
|
735 | $ 35.08 | -0.36 % | $ 2.03 B | ||
|
Akebia Therapeutics
AKBA
|
42 | $ 1.39 | 0.36 % | $ 357 M | ||
|
I-Mab
IMAB
|
-1.97 K | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | ||
|
Alnylam Pharmaceuticals
ALNY
|
46.6 | $ 331.14 | 3.85 % | $ 43.4 B | ||
|
Altimmune
ALT
|
7.85 K | $ 3.4 | 1.8 % | $ 300 M | ||
|
Amgen
AMGN
|
217 | $ 344.03 | -1.12 % | $ 185 B | ||
|
Midatech Pharma plc
MTP
|
82.8 | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | ||
|
Amneal Pharmaceuticals
AMRX
|
117 | $ 12.27 | -1.68 % | $ 3.85 B | ||
|
Anika Therapeutics
ANIK
|
270 | $ 14.99 | 1.28 % | $ 220 M | ||
|
Acorda Therapeutics
ACOR
|
117 | - | -24.86 % | $ 820 K | ||
|
ANI Pharmaceuticals
ANIP
|
235 | $ 73.8 | -0.55 % | $ 1.43 B | ||
|
Advaxis
ADXS
|
-143 K | - | -9.65 % | $ 45.9 M | ||
|
Aptorum Group Limited
APM
|
-400 | $ 0.88 | -5.16 % | $ 4.8 M | ||
|
Aquestive Therapeutics
AQST
|
-172 | $ 4.12 | -0.24 % | $ 441 M | ||
|
Aeterna Zentaris
AEZS
|
-34.3 K | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | ||
|
AIkido Pharma
AIKI
|
-1.92 | - | 1.93 % | $ 17.4 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
21.2 | $ 8.14 | 1.31 % | $ 223 M | ||
|
Ardelyx
ARDX
|
885 | $ 5.99 | 0.84 % | $ 1.44 B | ||
|
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - | ||
|
Arcutis Biotherapeutics
ARQT
|
158 | $ 24.06 | 1.82 % | $ 3.06 B | ||
|
Arvinas
ARVN
|
4.66 | $ 10.87 | 0.14 % | $ 771 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
8.75 | $ 60.28 | -1.23 % | $ 8.06 B | ||
|
Assembly Biosciences
ASMB
|
25.1 | $ 29.51 | 1.72 % | $ 331 M | ||
|
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B |